Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? - Wikidata - awgldk - TriplyDB

Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

http://www.wikidata.org/entity/Q35024962

about

Ameliorating Role Exerted by Al-Hijamah in Autoimmune Diseases: Effect on Serum Autoantibodies and Inflammatory Mediators Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype.Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.PharmGED: Pharmacogenetic Effect Database.Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview.Pharmacogenetics of methotrexate.Associations between C677T and A1298C polymorphisms of MTHFR and susceptibility to rheumatoid arthritis: a systematic review and meta-analysis.The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies.Global pharmacogenetics: giving the genome to the masses.T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias Mechanisms underlying methotrexate-induced pulmonary toxicity.Pharmacogenetics of psoriasis.Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity.Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model.Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis.Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis.Population distribution of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C risk alleles for methotrexate toxicity in Israel.Plasma total homocysteine level and methylenetetrahydrofolate reductase 677C>T genetic polymorphism in Japanese patients with rheumatoid arthritis.Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis.

P2860

Q26797089-4A9CCF4D-1449-47E4-BC50-1E490860E7C8 Q34235121-92A61B39-BA9B-4B1F-9C64-6DF626DC7D62 Q34293811-B48F5E82-C4F7-4B7F-B137-39D049EE7B4D Q35555878-6EC98697-B2CE-428B-BA06-CCCDC5EB865D Q35567962-61F705FE-1ABD-4411-ADD9-CC56D6A01A3B Q35744255-714CAC6B-5CCD-41FF-9795-9C17D55B9729 Q35911142-38DA0BD0-7C9C-4873-9E5E-728B7B25BDD7 Q36273637-9AC5847F-B419-4ADC-BA3A-B991CC49A0E3 Q36286418-E5053C86-4014-453B-B27B-1BF8F658F213 Q36441438-48CCC5F6-11C1-4E62-8F87-745C31CB3950 Q36497092-17E20471-1DAA-4CAD-8DC9-840037959F0F Q37042046-97CB1498-9758-4DBB-9C5A-6232A6F796B2 Q37524010-6500F2DF-1D1D-4AC1-9E0B-ED3841B24A9C Q37822759-C8C1A108-7D8A-4A46-8D3E-D61D12B69B2A Q41808826-1C2157FD-92FA-4927-975B-115B313D2FF1 Q41934162-B6A6C57A-ED58-4388-8187-FF7B152DFAC9 Q42135873-2229F1F3-1312-4B13-9E88-388E4E61AD47 Q42597675-82A72AB8-DB2E-4B33-9428-76543D72CB72 Q44948330-24D68D82-E633-48DE-AF72-1FBE7ABF9946 Q45831620-B73730CF-4254-469F-9B56-2CB6541C0B92 Q46090014-41BFB265-8BEC-409B-8E91-867DFB4AE8D3 Q51320020-884282F0-B9CB-4FB6-AE58-64761CCBC083

P2860

Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

http://www.wikidata.org/entity/Q35024962

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Will pharmacogenetics allow be ...... nts with rheumatoid arthritis?

@ast

Will pharmacogenetics allow be ...... nts with rheumatoid arthritis?

@en

type

label

Will pharmacogenetics allow be ...... nts with rheumatoid arthritis?

@ast

Will pharmacogenetics allow be ...... nts with rheumatoid arthritis?

@en

prefLabel

Will pharmacogenetics allow be ...... nts with rheumatoid arthritis?

@ast

Will pharmacogenetics allow be ...... nts with rheumatoid arthritis?

@en

P1433

Q35024962-65BE4C78-45DC-46D3-B805-2F880DC2D63F

P1476

Q35024962-9C520A83-F277-4AF6-BAB0-2A7E9410D2AB

P2093

Q35024962-244A860E-E22F-4838-9989-92A38A8AFE39

Q35024962-5B4F8F9E-A456-42CA-B319-FA0D923AFCD4

Q35024962-77003378-8B99-43F3-81A0-058C8F02F7C3

Q35024962-D4C8AA84-EC83-4629-9A5D-7A24F18EC004

P2860

Q35024962-0110739A-8F23-458D-9670-EAE79E6B84E6

Q35024962-08626481-CDB9-4A7A-A9BC-28210F508F22

Q35024962-131165A3-596A-408F-A39D-1F6F5D8B3F8C

Q35024962-2312EC16-5BDF-4B99-A2FF-09EB4BD75775

Q35024962-2910BA80-DD13-4857-91C8-CCA9FF18B972

Q35024962-2D511806-4165-49CC-B15D-F713A70E4C43

Q35024962-3D389A8B-A539-4046-BBF3-F410503D815B

Q35024962-41E2186C-B832-40BE-A32A-1373C813E18D

Q35024962-462278E7-604C-477B-8CDF-D4BC7EF33B5E

Q35024962-4FED3644-E7EF-4CD7-90FF-AE4A4BDB77BC

P304

Q35024962-CE36ED3A-1363-4493-8BC8-CF1C3AF8EBB1

P31

Q35024962-18816FD2-E2B9-48D2-88D3-D22257832A48

P356

Q35024962-52A4F37C-B10C-4CD2-A821-7E5074E784AA

P407

Q35024962-3B3AAB1F-E174-49AE-BD91-A89805B83585

P433

Q35024962-55AE7A2B-73B7-49C2-9457-2F8B936F2848

P478

Q35024962-3706770C-B4B0-491A-9459-7980C4CBB08D

P577

Q35024962-1906DBC2-46BE-424F-B0D0-00E79600A68E

P5875

Q35024962-B5F8BF9A-A23C-496B-8B27-1D3F59540DAD

P698

Q35024962-D6E51184-2F27-48A4-9118-85B1749C7424

P932

Q35024962-00AD41F5-199F-413E-ACB1-2BCF5EF3DCB3

P356

P1433

Annals of the Rheumatic Diseases

P1476

Will pharmacogenetics allow be ...... nts with rheumatoid arthritis?

@en

P2093

H L McLeod

http://www.w3.org/2001/XMLSchema#string

P Ranganathan

http://www.w3.org/2001/XMLSchema#string

S Eisen

http://www.w3.org/2001/XMLSchema#string

W M Yokoyama

http://www.w3.org/2001/XMLSchema#string

P2860

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition.

Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis.

Pharmacogenomics: translating functional genomics into rational therapeutics.

The costs of rheumatoid arthritis: an international long-term view.

Pharmacogenomics: unlocking the human genome for better drug therapy.

Rational use of new and existing disease-modifying agents in rheumatoid arthritis.

Pharmacological and biochemical aspects of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase.

P304

4-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.62.1.4

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10991599

http://www.w3.org/2001/XMLSchema#string

P698

12480661

http://www.w3.org/2001/XMLSchema#string

P932

1754300

http://www.w3.org/2001/XMLSchema#string